Athira Pharma has dosed the first subject in the Phase I clinical trial of its treatment candidate, ATH-1020, to potentially treat neuropsychiatric conditions. An orally available, brain-penetrant small molecule, ATH-1020 is created to boost HGF/MET system. The first-in-human placebo-controlled, randomised, double-blind, two-part trial will assess the safety, tolerability and pharmacokinetics of single and multiple ascending doses of […]

NeuroSense Therapeutics plans to enroll 70 patients with fast-progressing amyotrophic lateral sclerosis (ALS) in its planned Phase IIb trial of PrimeC, CEO Alon Ben-Noon says. The trial will randomise patients 2:1 between PrimeC and placebo during a blinded six-month treatment period, followed by a six-month, open-label treatment period, he adds. PrimeC is an extended-release version […]

Alcohol Use Disorder (AUD) affects 6.7% of drinking adults. Some of the symptoms of AUD, as listed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), include being unable to reduce alcohol use despite a desire to do so, a need to drink that has become distracting, continuing to drink despite harm caused and experiencing symptoms of withdrawal […]